News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PolyTherics and Spirogen Ltd. Announce a Research Collaboration to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer


4/2/2012 10:25:04 AM

LONDON--(BUSINESS WIRE)--PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited ("Spirogen"), a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES